Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study - 10/11/18
Abstract |
Background |
Cutaneous adverse events are common with programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors. However, the nature of the specific cutaneous adverse event of dermatitis has not been investigated across various PD-1/PD-L1 inhibitors. Oncologic outcomes potentially associated with dermatitis are not well characterized.
Objective |
To assess the nature of dermatitis after exposure to a PD-1/PD-L1 inhibitor and oncologic outcomes associated with dermatitis.
Methods |
Retrospective, matched, case-control study conducted at a single academic center.
Results |
The most common histologic patterns were lichenoid dermatitis (50%) and spongiotic dermatitis (40%). The overall tumor response rate was 65.0% for the case patients and 17.0% for the controls (P = .0007) (odds ratio, 7.3; 95% confidence interval, 2.3-23.1). The progression-free survival and overall survival times were significantly longer for the case patients than for the controls by Kaplan-Meier analysis (P < .0001 and .0203, respectively).
Limitations |
The retrospective design and relatively small sample size precluded matching for all cancer types.
Conclusions |
Lichenoid and spongiotic dermatitis associated with PD-1/PD-L1 inhibitors could be a sign of robust immune response and improved oncologic outcomes. The value of PD-1/PD-L1–related dermatitis in predicting cancer outcomes awaits investigation through prospective multicenter studies for specific cancer types.
Le texte complet de cet article est disponible en PDF.Key words : checkpoint inhibitor, dermatitis, immunotherapy, inhibitor, lichenoid, nonmelanoma skin cancer, PD-1, PD-L1, programmed death 1, programmed death ligand 1, reaction pattern, spongiotic
Abbreviations used : AE, BOR, CI, FDA, ORR, OS, PD-1, PD-L1, PFS
Plan
| Funding sources: Mr Lee was supported by the Stanford Medical Scholars Research Program. The Stanford Cancer Institute Research Database is supported by a National Cancer Institute Cancer Center support grant (5P30CA124435) and a Stanford National Institutes of Health/National Center for Research Resources Clinical and Translational Science award (UL1 RR025744). |
|
| Disclosure: Dr Chang is a clinical investigator for Merck and Regeneron unrelated to the current study. Mr Lee, Ms Li, Mr Tran, Dr Zhu, Dr Kim, and Dr Kwong have no conflicts of interest to disclose. |
|
| Presented as a poster at the American Academy of Dermatology Annual Meeting, San Diego, CA, February 16-20, 2018. |
Vol 79 - N° 6
P. 1047-1052 - décembre 2018 Retour au numéro
Article précédent
- CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases
- Akihiko Yuki, Satoru Shinkuma, Ryota Hayashi, Hiroki Fujikawa, Taisuke Kato, Erina Homma, Yohei Hamade, Osamu Onodera, Masao Matsuoka, Hiroshi Shimizu, Hiroaki Iwata, Riichiro Abe
- Natural history of disease activity and damage in patients with cutaneous lupus erythematosus
- Khor Jia Ker, Noelle M. Teske, Rui Feng, Benjamin F. Chong, Victoria P. Werth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?